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Abstract: Cancer is probably the number one research area among all human endeavors, receiving the largest portion of science funding
in most countries. This is because cancer remains one of the oldest conundrums among all human maladies. Although we now have
a greater understanding of the biological and molecular basis of cancer, its diagnosis and therapy still pose great challenges. In this
review, our aim is not to establish a comprehensive understanding of cancer, which is essentially impossible, but to outline, in a more
provocative way, why cancer research in the pursuit of a cure did not live up to its promise, as the death rate from cancer has not changed
much after almost half a century. In addition, we discuss some future perspectives to give some insight into cancer research and debunk
the old view that pouring money into cancer research is the only way to overcome this dreadful disease.
Key words: Cancer, cancer research, cancer statistics, progress in cancer, cancer publications

1. Introduction
The term ‘carcinos’, meaning ‘cancer’, was first used by
Hippocrates (460–370 BC) long before the terms ‘biology’,
‘chemistry’, or ‘physics’ were around. The causes of this
disease have puzzled researchers and practitioners from
the earliest times to date. Today, there is no single metabolic
pathway or signal transduction network that cancer has
not been associated with. Cancer is regarded as a group
of complex genetic disorders resulting from mutations at
multiple genetic loci and discovery of an ever-increasing
number of cancer genes is opening up new scenarios in
cancer genetics. Since the discovery of the first tumorcausing viral RAS genes 50 years ago (Harvey, 1964) and
their human analogs (i.e. HRAS, NRAS) more than 30 years
ago (Der et al., 1982; Parada et al., 1982), new cancer genes
are discovered steadily (Vogelstein et al., 2013; Lawrence
et al., 2014). In just a decade, the number of cancer genes
discovered increased from 291 to 523 (Futreal et al., 2004).
Today, there are 280 cancer research centers and
institutes in the world; of these, 68 are National Cancer
Institute (NCI) designated cancer centers in the United
States. They have significant budgets dedicated to research
in the development of more effective approaches to
prevention, diagnosis, and treatment of cancer (http://
www.cancerindex.org/clinks1.htm). According to the
International Agency for Research on Cancer (IARC),
the estimated total annual economic cost of cancer was
* Correspondence: hikmet.geckil@inonu.edu.tr

approximately US$ 1.16 trillion in 2010, the equivalent of
more than 2% of the total global gross domestic product.
For the scientific world, cancer research has been a winwin situation. Today, the number of publications made,
grants earned, and funds allocated in cancer research far
exceed any other scientific endeavors. In the last decade,
the number of articles with the term “cancer” in the title
increased almost 3-fold (Figures 1 and 2). As of May 2014,
the Thomson Reuters Science Citation Index Expanded
covered 8636 science journals, 275 of which are classified
as “cancer journals” (more than 3% of all journals). Of
these cancer journals, 90 had “cancer” as part of the title.
This is most probably the trend for books and budgets on
cancer.
Despite the extent of research and resources devoted
to cancer, it remains one of the most common deadly
diseases. In most societies, about 20% of all deaths are
from cancer, second only to cardiovascular diseases. The
GLOBOCAN project of IARC, which provides estimates
for the incidence, mortality, and prevalence of cancer for
184 countries, shows that the incidence of cancer increased
from 12.7 million in 2008 to 14.1 million in 2012. This
trend is projected to continue and bring the number of
cancer cases close to 25 million over the next 2 decades
(Ferlay et al., 2010). In the NCI’s SEER*Stat database, which
provides information on cancer statistics in the USA, the
estimates for new cases of cancer and cancer deaths in
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Figure 1. The ratio of articles with the term “cancer” in their titles
to all articles in PubMed (Medline). Data were compiled online
(http://dan.corlan.net/medline-trend.html).

2014 are 1,665,540 and 585,720, respectively. Cancer in
Turkey, like in most other countries, is the second-highest
cause of death, just after cardiovascular deaths. However,
knowledge of cancer epidemiology in Turkey is still in
its infancy, as most health providers did not require a
correlative data for cancer registries until recently. The
2014 projections of the Ministry of Health of Turkey for
the number of people with cancer and cancer deaths are
about 150,000 (207/100,000) and 60,000, respectively.
The signing of the National Cancer Act of 1971
by President Richard Nixon is generally viewed as the
beginning of the war on cancer (US Senate, 1971). In his
‘State of the Union’ address, Nixon declared that “the time
has come in America when the same kind of concentrated
effort that split the atom and took man to the moon should
be turned toward conquering this dread disease”. About 30
years later, at the Human Genome Announcement in 2000,
President Clinton ventured that “it is now conceivable that
our children’s children will know the term cancer only as a
constellation of stars”.
Decades have passed since these declarations and
statements on cancer. Their prophecy remains unfulfilled
and cancer research has yet to live up to its promise.
Cancer, time and again, proves that it is one of the most
challenging and least understood of all human maladies,
even harder than cracking the atom or putting man on the
moon.
2. What makes cancer so different from other diseases?
As the title (“Cancer: normal cells’ reply to a deadly fate”)
of this special issue of the Turkish Journal of Biology
rightly suggests, for a normal cell destined to die, given
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Figure 2. The number of articles with the term “cancer” in their
titles. Data were compiled from the Science Citation Index
Expanded (http://thomsonreuters.com/science-citation-indexexpanded/). This index gives no information about the total
number of publications recorded for each year.

the accumulation of all kinds of defects over its lifetime,
turning to a cancerous state is a salvation at the expense
of the host (i.e. the organism). In other words, turning
cancerous is an intrinsic property of cells and is a defense
and survival mechanism for the cells under threat. Though
it can result in host mortality, cancer is a favorable state
for the cells as it allows them a growth advantage and near
immortality.
Contrary to many other common diseases, cancer is
generally not caused by a single cause such as a pathogen
or even, in most cases, a single gene. Most human diseases
are caused either by a single gene affecting a specific tissue
or by exogenous sources (e.g., infectious agents), both of
which can be specifically targeted for potential treatment.
This is why some cancers can be prevented (e.g., cervical
cancers and some liver cancers) through vaccination
against their causative agents (i.e. the human papilloma
virus and hepatitis B virus) (Carlos et al., 2010). Conversely,
cancer is a disease of all tissues or organs, resulting from
endogenously and selectively produced clones of cells,
as discussed below. Like normal cells, cancer cells are no
foreigners to the organism.
Cancer is a remarkably complex heterogeneous
collection of diseases. Recent studies show that even a
single tumor has phenotypic variability among its cells and
that there is significant genomic heterogeneity between
histologically similar tumors (Gerlinger, 2012; Swanton,
2012). This heterogeneity reflects the action of the twin
evolutionary forces of variation generation and selection,
contributing to the fast-evolving characteristics of cancer
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cells (Yates and Campbell, 2012). Due to the harm done
to the cell’s own repair mechanism, cancer genomes are
riddled with mutations. Once the protective shield of cells
is harmed (e.g., DNA repair genes), genomes accumulate
more and more mutations and the interior and the exterior
of cells are in a shambles. It is these mutations that wreak
havoc in the cellular machinery, leading cancer cells to
confer oncogenic properties such as growth advantage,
tissue invasion and metastasis, angiogenesis, and evasion
of apoptosis (International Cancer Genome Consortium
et al., 2010). Each cancer is characterized by numerous
somatic mutations. Some are called “drivers” and cluster
within cancer genes, while others are called “passengers”
and are more or less randomly distributed. While drivers
are the cause of cancer, passengers, which outnumber
drivers, are thought to be the consequence of cancer.
In a hypermutated genome, a characteristic of many
cancer genomes, determining which mutations are the
cause and which mutations are the consequence of cancer
is challenging. It is reported that most cancers arise from
cells having 2 to 8 driver gene mutations, the remaining
being passengers that confer no selective growth advantage
(Vogelstein et al., 2013). Although identification of all the
altered genes in a tumor is not a difficult task today thanks
to high-tech sequencing technologies and bioinformatics
tools (International Cancer Genome Consortium et al.,
2010), assigning the exact roles of drivers and passengers
still remains elusive. Studies showed that some passenger
mutations could turn into drivers during tumorigenesis.
Mutations in a wide range of genes cause chromosomal
instability by as of yet undefined mechanisms that play
roles in the cancer cell genome’s numeric (aneuploidy) or
structural character (Yates and Campbell, 2012). It is now
well established that aneuploidy is the main driver of the
chaotic state of cancer cells, resulting in rampant disorder
not only in genomes but also in a myriad of molecular
inventories and reaction repertoires.
There are about 200 different types of cancers, a
number close to the number of cell types (or tissues) in
the human body (Ferrari, 2013). No other disease can
even come close to this variability. Although different
cancer cells share similar basic characteristics, such as
the ability to reproduce vigorously, each type of cancer
is unique with its own causes and consequences. One of
the biggest enigmas in cancer research is how cancer cells
from a specific tissue or organ can find a niche in their new
environment (i.e. in the new tissue) after a long metastatic
travel. We know that each of the almost 200 tissues in
the human body is composed of its distinct cells with the
same genome but different sets of proteins, metabolites,
metabolic requirements, and so on. How a metastatic
cancer cell parasitizes a different tissue and eventually
invades it is still a mystery.

Just a we communicate by language, the language of
cells is touch. Each of a myriad of intra- and intercellular
molecules plays its role by touching a plethora of others,
relaying information to the respective destinations. All
these touch and transfer interactions over long-distance
pathways in a crowded milieu are intricately regulated
in normal cells. In other words, molecular talk is highly
regulated and specific in normal cells. In cancer cells,
however, this process is loose due to hypermutated
genes and thus changes in coding and noncoding RNA
transcripts. The defects in proteins and other molecules
in a cancer cell cause unprecedented and deregulated
molecular touch and transfer. Thus, contrary to a normal
cell in which information flow is highly specified over long
distances, a cancer cell is in complete disarray with its
fragmented information flow, endowing it with multiple
selective advantages. It is this redundancy in the system
that allows cancer cells to find alternative pathways to cope
with and adapt to changes in their environment.
3. Cancer: then and now
Of the 52.8 million deaths globally in 2010, 8 million were
from cancer (15% of all deaths). This cancer death rate
was 38% more than 2 decades ago (Lozano et al., 2012).
With 14 million new cases and 8.2 million deaths, cancer
worldwide contributed to 15% of all deaths in 2012 (May
2014). According to the IARC’s latest predictions, these
figures are expected to rise to 22 million new cases and 13
million deaths annually within the next 2 decades.
More than 4 decades have passed since the National
Cancer Act was signed (US Senate, 1971), but there has
only been about a 10% decline in cancer deaths in the
United States (Jemal et al., 2010). Even this meager
progress is contested: was the decline the result of major
breakthroughs and treatment or prevention? Over 1.6
million new cancer cases and 600,000 cancer deaths are
projected to occur in the United States in 2014. Today, 1
in 4 deaths in the United States is due to cancer (Siegel et
al., 2014).
The toll of cancer in the world not only causes human
catastrophe but also inflicts a heavy social and economic
burden. It strains national healthcare systems, especially
in those countries with an aging population. Cancer poses
a significant threat to national economies and to the global
economic system, as the world has spent several hundred
billions of dollars on research in the quest for a cure for
cancer in the last 4 decades (Eckhouse et al., 2008). This
is why the World Economic Forum lists cancer as the
noncommunicable disease with the most likely and most
severe risks to the global economy (World Economic
Forum, 2011).
The number of scientific papers, books, projects, and
patents with the term “cancer” in the title most probably
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far exceeds any other topic in all the sciences. The number
of scientific articles with the word “cancer” have almost
tripled every decade (Figures 1 and 2), with the top 20
publishing countries having the biggest share (Figures 3
and 4). A decade ago, the total number of cancer genes
accounted for about 1% of the human genome. Now
this figure is 2%. Major international projects, such as
the Cancer Genome Atlas and the International Cancer
Genome Consortium, are underway, aiming to create a
comprehensive catalog of all the genes responsible for the
initiation and progression of cancer.
With rare exception, once a cancer metastases the
likelihood of surviving the cancer today is about what it
was 40 years ago. What is more, the obesity problem and
the sedentary lifestyle in today’s society are expected to
increase the morbidity and mortality rate of cancer in the
coming decades and will further inflict a crushing burden
of economic costs and human suffering. Except for a few
cancers (e.g., testicular cancer, some childhood leukemias,
and lymphomas), we still have no cure for cancers once the
disease is metastasized. The death rates of some cancers are
rising, especially those associated with obesity and a lack of
exercise, such as colon, kidney, pancreas, and liver cancers.
Considering the plethora of new findings compared with a
decade or so ago, the cancer puzzle today is more troubling
than ever. One thing is for sure: the more we know about
cancer, the less we understand it. Every answer in cancer
research brings more questions.

Figure 3. Top 20 countries in cancer publications based on
number of articles with “cancer” in the title between 2008 and
2012 (5-year coverage). Total number of publications in this
period was 3,021,402. Percentage value for each country is the
ratio of cancer articles in that country to total cancer articles
across all 20 countries. Two-letter country codes are from the
International Organization for Standardization. Data were
compiled online (http://dan.corlan.net/medline-trend.html).

4. Future perspectives
Our cells do not reside in a vacuum. Except for circulating
blood cells, most of our cells are anchored in their places
in a specific milieu in a specific tissue. Besides inherited
defects that we receive from our parents in the first place,
inefficiencies in the replication of genetic material and its
constant exposure to a myriad of insults during a lifetime
cause mutations known or suspected (now over a million)
to have roles in cancer (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic/). How these various
mutations hijack normal cellular processes to promote
cancer still remains a mystery.
As was the case for classic biochemical and genetic
studies for decades, cancer research also followed a
reductionist path (e.g., investigation of single proteins
or genes) to determine how cancer cells differed from
normal cells. Now we know that cancer deserves a holistic
approach, more so than any other human ailment, as it is
caused not only by relevant genetic mutations but also by
epigenetic marks (methylation in DNA and acetylation
in chromosomal proteins) that also alter gene expression,
metabolism, and cellular signaling. These epigenetic
factors, by turning switches on and off, affect the expression
of genes without causing mutations.

Epigenetic marks are the response of our genome to
environmental changes. This response can have a longterm impact on the activity of our genes. If DNA is the
“naked body”, then one can think of epigenetic marks
as the “clothing”. Circumstances (e.g., lifestyle) cause
the naked body to dress differently and thus behave
differently. Thus, the whole genome is highly dynamic and
never static. Recent studies show that overexpression and
downregulation of genes through epigenetic alterations
and dysregulations are deeply involved in cancer initiation
and progression (Maruyama et al., 2012; Timp and
Feinberg, 2013).
With the advent of massively parallel sequencing
tools and technologies, now the high-resolution
characterization of the whole genome, transcriptome, and
epigenome of cancer cells is within our reach. However,
such technologies only give us the tools to acquire data.
The analysis of these data to interpret how a cancer cell
initiates and progresses is the main challenge. In this
context, it is striking that a complete understanding of
the human oncogene (RAS) is still lacking, even though
it was discovered 3 decades ago and is among the most
studied and best characterized of the cancer-causing genes
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(Malumbres and Barbacid, 2003). Although RAS genes are
the most frequently mutated oncogenes in human cancers,
with a prevalence of 1 in every 3 cases, no effective drug
for the inhibition of the RAS oncoprotein has yet reached
the clinic (Baker and Der, 2013). This is also the case with
many other well-known oncogenes (e.g., MYC).
A complete understanding of cancer is still limited
by many complexities and constraints. While each tumor
is substantially different from others, in most cases
even cells in a single tumor are slightly different from
one another in terms of their mutated genetic makeup,
aberrant metabolism, and other cellular pathways. Thus,
a single model of such disarrays would not suffice, given
the heterogeneity of tumors and even cells within a
single tumor. Pinpointing a potent long-term therapeutic
approach for many thousands of such targets (discrepancy)
in a tumor is a hard task, let alone addressing these cells’
fast-changing responses to treatment.
Indeed, it is now well accepted that virtually all cancers
result from the accumulated mutations in genes that
increase the fitness of a tumor cell over that of the cells
surrounding it (Axelrod et al., 2006; Huang, 2013). When
acquired mutations increase the fitness of a cell, that cell
will generate more daughter cells than its neighboring
cells. The result is the clonal expansion of mutant cells, a
signature of natural selection (Greaves and Maley, 2012).
Studies show that a genetically programmed cellular
rewiring in cancer cells causes metabolic outliers that
satisfy these cells’ demands for growth and proliferation.
The evolution of massive alterations in cancer cells gives
these cells an edge in the competition to win out over
normal cells. Given their continuous proliferation, cancer
cells are programmed to synthesize the building blocks
(amino acids, nucleotides) necessary to support biomass

production rather than energy generation. Even in the
presence of sufficient oxygen, cancer cells preferably carry
out a type of metabolism that is indeed reserved for rapid
energy demand (Cantor and Sabatini, 2012). As mentioned
above, cancer cell genomes are riddled with mutations that
may impair the function of a number of genes taking part
in aerobic metabolism compared to a small number of
genes involved in anaerobic metabolism. Although crucial
for an understanding of cancer biology, these metabolic
perturbations are challenging to quantify, given the
dauntingly large number of reactions and metabolites in a
typical cell (DeBerardinis and Thompson, 2012).
All these points are evidence that cancer will remain
the most challenging of all human struggles. Given their
millions of years of evolutionary acumen, cancer cells
defend themselves in remarkable ways. Thus, a “silver
bullet” for all cancers seems to be an unrealistic dream.
However, some characteristics unique to almost
all cancers can be explored and exploited as potential
therapeutic targets. Compared with normal cells, cancer
cells have a highly auxotrophic character due to their
highly mutated phenotype (e.g., defects in enzymes).
Thus, for their survival and perpetuation, cancer cells are
more dependent on external sources for many nutrients
(e.g., the amino acids methionine and asparagine) for
which they do not have a functional pathway of synthesis.
This requirement is supplied either by normal cells or
through diet. Thus, the rapid and complete depletion of
the circulating pool of such nutrients impairs protein
synthesis and leads to a delayed inhibition in DNA and
RNA synthesis. Such impairment of cellular function
renders cancer cells sensitive to death signals (Muller and
Boos, 1998; Lu et al., 2003; Geckil et al., 2004; Delage et al.,
2010; Agrawal et al., 2012).

705

ERENLER and GEÇKİL / Turk J Biol
Another track to explore for cancer diagnosis and
treatment takes into consideration not only these
cells’ physiology but also their physics (Wirtz et al.,
2011; Zhang and Austin, 2012; Jain, 2014; Moore and
Nagahara, 2014). To date, research has overwhelmingly
been directed towards the biochemistry and genetics
of cancer cells. Now, however, we know that cancer
cells bear distinct biomechanical characteristics (e.g.,
entropy, rheology, force, adhesion). These characteristics
contribute to the plasticity in the detachment, migration,
habituation, growth, proliferation, and invasion of
cancer cells. If life feeds on negative entropy as stated by
the physicist Erwin Schrödinger (von Stockar and Liu,
1999), cancer cells feed on positive entropy given their
more chaotic molecular crowding. Indeed, most cancer
cells are auxotrophic in metabolism. On the contrary,
the higher organization (low entropy) of normal cells is
maintained and sustained through long tracks of perfectly
functioning metabolic and signaling pathways at highenergy demand. In a normal healthy cell, information
flow is highly specified (low entropy), whereas in a cancer
cell it is fragmented and defective (high entropy), which

gives the cell the plasticity to switch to different signaling
pathways and cellular metabolic activities under strained
conditions. Quantitative theories that relate these physical
spatiotemporal interactions of metastatic cells to the
new microenvironment can provide us with a better
understanding of the disease and more effective treatment
strategies.
Although our inborn genetic make-up plays a pivotal
role in our fate, it is estimated that between one-third
and one-half of cancer deaths could be avoided with
prevention, early detection, and treatment (Stewart and
Wild, 2014). The estimate shows that the world could have
saved between $100 and $200 billion in 2010 by investing in
the prevention, early detection, and effective treatment of
cancer. Obesity and sedentary lifestyle in today’s societies
seem to be the biggest obstacles to achieving this goal.
Finally, once they are no longer concerned with funds
or the entangled interests of industry, or strained by
continuous reporting and appraisals, cancer researchers
and institutions will have better success in finding new
avenues for cancer diagnosis and treatment.
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